Journal
TRENDS IN BIOTECHNOLOGY
Volume 35, Issue 11, Pages 1062-1073Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2017.07.004
Keywords
-
Categories
Funding
- Wellcome Trust [104978/Z/14/Z]
- Leverhulme Trust [RPG-2016-015]
- LongeCity
- Methuselah Foundation
- Wellcome Trust [104978/Z/14/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available